Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albumin granulocyte colony stimulating factor fusion protein - Beijing BioFortune/Tianjin SinoBiotech

Next Previous
Drug Profile

Albumin granulocyte colony stimulating factor fusion protein - Beijing BioFortune/Tianjin SinoBiotech

Alternative Names: Albumin-GCSF-fusion-protein-Beijing-BioFortune/Tianjin-SinoBiotech; HSA-G-CSF-fusion-protein-Beijing-BioFortune/Tianjin-SinoBiotech; HSA-GCSF; Human Serum Albumin GCSF; Human-serum-albumin/granulocyte-colony-stimulating-factor-fusion-protein-Beijing-BioFortune/Tianjin-SinoBiotech; Recombinant-albumin-granulocyte-colony-stimulating-factor-fusion-protein-Beijing-BioFortune/Tianjin-SinoBiotech; rHSA/GCSF fusion protein - Beijing-BioFortune/Tianjin-SinoBiotech

Latest Information Update: 28 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Bio-Fortune; Tianjin SinoBiotech
  • Class Albumins; Granulocyte colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 31 Mar 2021 Albumin granulocyte colony stimulating factor fusion protein is still in phase II trials in Neutropenia (Prevention) in China (SC)
  • 31 Mar 2021 Tianjin SinoBiotech plans a phase III trial for Neutropenia (Prevention) (SC)
  • 24 Apr 2019 Tianjin SinoBiotech completes a phase II trial for Neutropenia (Prevention) in China (SC) (NCT03251768)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top